Works by van Erp, N. P.

Results: 8

Use of incretin agents and risk of pancreatic cancer: a population-based cohort study.

Published in:

Diabetes, Obesity & Metabolism, 2016, v. 18, n. 3, p. 258, doi. 10.1111/dom.12605

By:

Knapen, L. M.;
van Dalem, J.;
Keulemans, Y. C.;
van Erp, N. P.;
Bazelier, M. T.;
De Bruin, M. L.;
Leufkens, H. G. M.;
Croes, S.;
Neef, C.;
de Vries, F.;
Driessen, J. H. M.

Publication type:

Article

Myelosuppression by sunitinib is flt-3 genotype dependent.

Published in:

2010

By:

van Erp, N. P.;
Mathijssen, R. H. J.;
van der Veldt, A. A.;
Haanen, J. B.;
Reyners, A. K. L.;
Eechoute, K;
Boven, E;
Wessels, J. A. M.;
Guchelaar, H-J;
Gelderblom, H

Publication type:

Letter

Real-world data on the management of pazopanib-induced liver toxicity in routine care of renal cell cancer and soft tissue sarcoma patients.

Published in:

Cancer Chemotherapy & Pharmacology, 2024, v. 93, n. 4, p. 353, doi. 10.1007/s00280-023-04615-7

By:

Westerdijk, K.;
Krens, S. D.;
Steeghs, N.;
van der Graaf, W. T. A.;
Tjwa, E. T. T. L.;
Westdorp, H.;
Desar, I. M. E.;
van Erp, N. P.

Publication type:

Article

Unintentional combining enzalutamide with a moderate CYP2C8 inhibitor in a patient with metastatic castration-resistant prostate cancer: a case report.

Published in:

2022

By:

Verhulst, S. H.;
Boerrigter, E.;
Ras, S.;
van Erp, N. P.;
Hamberg, P.

Publication type:

Case Study

Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer.

Published in:

2016

By:

Wit, D.;
Schneider, T.;
Moes, D.;
Roozen, C.;
Hartigh, J.;
Gelderblom, H.;
Guchelaar, H.;
Hoeven, J.;
Links, T.;
Kapiteijn, E.;
Erp, N.;
de Wit, D;
Schneider, T C;
Moes, D J A R;
Roozen, C F M;
den Hartigh, J;
Guchelaar, H J;
van der Hoeven, J J;
Links, T P;
van Erp, N P

Publication type:

journal article

A pharmacological rationale for improved everolimus dosing in oncology and transplant patients.

Published in:

British Journal of Clinical Pharmacology, 2018, v. 84, n. 7, p. 1575, doi. 10.1111/bcp.13591

By:

ter Heine, R.;
van Erp, N. P.;
Guchelaar, H. J.;
de Fijter, J. W.;
Reinders, M. E. J.;
van Herpen, C. M.;
Burger, D. M.;
Moes, D. J. A. R.

Publication type:

Article

Clinical validation study of dried blood spot for determining everolimus concentration in patients with cancer.

Published in:

European Journal of Clinical Pharmacology, 2018, v. 74, n. 4, p. 465, doi. 10.1007/s00228-017-2394-0

By:

Willemsen, A. E. C. A. B.;
Knapen, L. M.;
de Beer, Y. M.;
Brüggemann, R. J. M.;
Croes, S.;
van Herpen, C. M. L.;
van Erp, N. P.

Publication type:

Article

Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial.

Published in:

2016

By:

Schneider, T C;
de Wit, D;
Links, T P;
van Erp, N P;
van der Hoeven, J J M;
Gelderblom, H;
Roozen, C F M;
Bos, M;
Corver, W E;
van Wezel, T;
Smit, J W A;
Morreau, H;
Guchelaar, H J;
Kapiteijn, E;
Schneider, Tatiana C;
de Wit, Djoeke;
Links, Thera P;
van Erp, Nielka P;
van der Hoeven, Jakobus J M;
Gelderblom, Hans

Publication type:

journal article